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ABSTRACT 
Training Support Vector Machines (SVMs) to predict 
drugs concentrations is often difficult because of the 
high level of noise in the training data, due to various 
kinds of measurement errors. We apply RANdom 
SAmple Consensus (RANSAC) algorithm in this paper 
to solve this problem, enhancing the prediction accuracy 
by more than 40% in our particular case study. A 
personalized sample selection method is proposed to 
further improve the prediction result in most cases.  
 
Keywords: RANSAC, SVM, drug concentration 
predictions 
 
1. INTRODUCTION 
The decision-making regarding the drug dosage has 
been one of the main challenges of the pharmacological 
studies for decades. Population Analysis is a classical 
method to decide a dosage. It looks at a small number 
of data points per patient over many subjects 
[Bourne1995]. The models built by this method are 
applied to any new patient in clinical practice. However, 
due to both intra- and inter-differences of patients' 
characteristics, these models are not always accurate, 
therefore not applicable to some drugs whose 
therapeutic ranges are narrow. Furthermore, Population 
Analysis methods suffer from other limitations, such as 
not considering specific features, e.g. binary values, and 
moreover the number of features is limited. The Support 
Vector Machine (SVM) algorithm has been applied to 
address these problems [You2011]. Nevertheless, the 
performance of this algorithm highly relies on the 
quality of the training dataset. When building the 
predictor, SVM minimizes a cost function where a 
mean-squared error is very sensitive to noise in input 
data. Clinical measurements are particularly faced with 
the risk of measurement errors. 
 RANdom SAmple Consensus (RANSAC) is a 
general parameter estimation method proposed to filter 
out the outliers (errors) from input data [Fischler1981]. 
It resamples the input data and generates candidate 
solutions with respect to a minimum number of 
observations (data points) required to estimate the 
underlying model parameters. Depending on a threshold 
value, the input data are classified with different 
proportions into inliers (good data) and outliers. Only 
the inliers are considered to be useful to build the SVM 
model for drug concentration predictions. Unlike other 
sampling techniques that use as many data as possible 
to obtain an initial solution and then prune the outliers, 
RANSAC uses the smallest set possible and then 
enlarges this set with consistent data points 
[Fischler1981]. It has been applied to various domains 
such as sensor networks [Buttyan2006, Furukawa2006, 
Shafique2008], Integrated Chip (IC)'s three-dimensional 
information recognition [Liang2011] etc. 
 In this paper, we use the RANSAC algorithm to 
filter the datasets before running a Support Vector 
Machine (SVM) algorithm. Compared to an SVM-
based algorithm in [You2011] and the Pharmacokinetic 
(PK) method [Widmer2006], it enhances the prediction 
by more than 40% in our experiments. Two scenarios 
for personalized predictions have also been tested to 
further improve the prediction accuracy. 
The paper is organized as follows: Section 2 
presents the methodology used in this paper. Section 3 
shows the experimental results and comparisons with 
previous works. Finally, Section 4 draws a brief 
conclusion. 
 
2. RELATED WORK 
 
In the literature, predictions of drug concentrations are 
usually carried out using analytical models. These 
models are built based on some assumptions that the 
system of human body is one-, two- or three-
compartment [Bourne1995, Bailey1991, Hahn2011]. 
This kind of assumption is widely applied to clinical 
practices nowadays, but suffers from some drawbacks 
such as it cannot take into account binary numbers and 
such as it is difficult to modify (add or remove) a 
parameter in the model. Thus, in [You2011], a Support 
Vector Machine (SVM)-based approach was proposed 
to overcome these drawbacks and tried to enhance the 
prediction accuracy. 
SVM [Boser1992] was introduced by Boser, 
Guyon and Vapnik and became rather popular in several 
domains e.g. pattern recognition, computer vision, etc. 
It is a supervised learning model with associated 
learning algorithms that analyze data and recognize 
patterns. It has been successfully applied to human 
detection [Dalal2005], object recognition [Pontil1998], 
image classification [Chapelle1999], etc. It is simple in 
computation but also robust in data classification and 
regression, compared with other common machine 
learning methods, e.g. decision trees, neural networks, 
etc. However, according to our survey, SVM has not yet 
been applied to estimating drug concentrations. 
To further enhance the performance of SVM, 
several previous works applied the RANdom Sample 
Consensus (RANSAC) algorithm. RANSAC, proposed 
by Fischler and Bolles [Fischler1981], is a general 
parameter estimation method used to deal with a large 
proportion of outliers in the input data. It was developed 
within the area of computer vision and applied to many 
other domains for data analysis. In [Nishida2008], the 
author claims a reduction of the computation 
requirement to about 1/170 compared with SVM 
libraries, and in [Kuo2007], RANSAC algorithm was 
used in a fine-selection stage for face recognition and 
achieved a lowest mean error rate. 
 
3. METHODOLOGY 
 
In this section, we will first introduce RANSAC 
algorithm that is used to improve drug concentration 
predictions together with Support Vector Machine 
(RANSAC-SVM). We will then propose a personalized 
drug concentration prediction scheme based on the 
RANSAC algorithm with two clinical scenarios. 
 
3.1. RANSAC Algorithm 
 
The RANSAC [Fischler1981] algorithm works as 
described in Algorithm 1. The number of trials N is set 
to be big enough to guarantee that at least one of the 
sets of possible inliers does not include any outlier with 
a high probability p. Usually p is set to 0.99. Let us 
assume, that u is the probability that any selected data 
point is an inlier, then v=1-u is the probability of 
selecting an outlier. N trials of sampling each K data 
points are required, where 1-p = (1-uK)N. This way: 
 
                                          (1) 
 
 The model of the RANSAC algorithm is a linear 
combination of several basis functions. The number of 
basis functions corresponds directly to the minimum 
number of points K required to fit the model. The 
parameters of the model are the weights of each basis 
function. In this paper, the drug concentration 
prediction method enhanced with filtering of the 
training dataset using RANSAC algorithm is called 
RANSAC-SVM method. 
 
3.2. RANSAC-based Personalization 
 
In Algorithm 1, inliers and outliers are separated 
without considering the information of a new patient. 
The SVM predictor for any new patient is estimated 
with the same inliers chosen as the training data. 
However, we believe that it might happen that the set of 
inliers for one patient is actually a set of outliers for 
another. Therefore, a predictor built out of the same set 
of inliers for a number of new patients might not be 
applicable for some others. Hence, it is important to 
find an individual set of inliers for each patient. So we 
propose to use RANSAC-based personalization method 
to solve this task. Previously [You2011], a 'closest 
point' strategy has been used which, despite using a 
much fewer number of training points (up to 30% of the 
total number), retains the initial performance of the 
original SVM (<3% degradation). However, that 
strategy needs a set of predefined weights for each 
feature in order to select the 'closest point'. 
Assume that we already have M samples from 
previous patients (our training dataset), for each new 
Algorithm 1 RANSAC algorithm, where data is a set of
observations, model is a model that can be fitted to data,
K is the minimum number of data points required to fit the
model parameters, N is the number of trials performed by
the algorithm, T is a threshold determining if a data point
fits a model, and bestmodel is the model fitting the highest
number of data points.
Input: data,model,K,N,T
Output: bestmodel
bestinliers← /0
for i= 1→ N do
possibleinliers← SampleUniformly(data,K)
possiblemodel← Fit(model, possibleinliers)
inliers← /0
for all point ∈ data do
if Distance(point,model)< T then
inliers← inliers∪{point}
end if
end for
if |inliers|> |bestinliers| then
bestinliers← inliers
end if
end for
return bestmodel← Fit(model,bestinliers)
a set of outliers for another. Therefore, a predictor built out of
the same set of inliers for a number of new patients might
not be applicable for some others. Hence, it is important
to find an individual set of inliers for each patient. So we
propose to use RANSAC-based personalization method to
solve this task. Previously [2], a ‘closest point’ strategy has
been used w ich, despite using a much fewer number of
training oints (up to 30% of th to al number), retains th
initial performance of the original SVM (<3% degradation).
However, that strategy n eds a et of predefined wei hts for
each feature in order to select the ‘closest point’.
Assume that we already have M samples from previous
patients (our training dataset), for each new patient we want
to find a best subset of samples of M to train the SVM.
To do so we treat them as if they were noisy samples of a
new patient, and use a RANSAC to remove the outliers. The
whole procedure is detailed in Algorithm 2. The new sample
from each patient is first replicated M times to make sure that
it will always be considered as an inlier. Then RANSAC is
applied to those replicated samples plus to the original M
training samples in order to predict the feature Y as a linear
combination of basis functions of the remaining features X .
The new patient sample is then removed from the inliers and
finally an SVM is trained on the remaining original training
samples to predict the drug concentration of this new patient.
Two clinical scenarios can be applied here: the target
feature Y is set as (1) any feature other than the concentration
value; (2)the measured drug concentration. For the scenario
(1), no invasive blood test is required, while in (2) the drug
concentration value should be measured after the first-dosing.
Algorithm 2 RANSAC-based personalized algorithm, where
training is a set of M training samples, newpatients is an
ordered set containing one sample per new patient , Y is the
index of a particular feature, model,K,N,T are parameters
of the RANSAC algorithm, and bestmodels is an ordered set
containg the SVM model fitting the best each new patient.
Input: training,newpatients,F,model,K,N,T
Output: bestmodels
bestmodels← /0
for all patient ∈ newpatients do
data← {patient, . . . , patient} {|data|=M}
data← data∪ training
inliers← RANSAC(data,model,K,N,T ) {predict Y}
inliers← inliers\{patient}
model← SVM(inliers)
bestmodels← bestmodels∪model
end for
return bestmodels
TABLE I
RANSAC BASIS FUNCTION ANALYSIS WITH RESPECT TO DIFFERENT
THRESHOLDS. T: THRESHOLD WITH UNIT [MG/L]. SCORE 0 STANDS FOR
‘UNUSED’ AND SCORE 1 FOR ‘IN USE’.
T x−2 x−1 x x2 x3 log(x) cos(x) 1− exp(−x) exp(x)
250 1 0 1 0 1 1 1 1 0
500 0 0 1 0 0 1 1 0 1
1000 0 1 0 0 0 0 1 1 0
1500 0 1 0 0 0 0 0 0 0
III. EXPERIMENTS AND COMPARISONS
The experiments are conducted on a set of data collected
during patients’ treatment with imat nib, a drug designed to
treat chronic myeloid leukemia a gast ointestinal stro al
tumors [6]. The training dataset consists of 54 patients and
252 samples, while the validation (testing) dataset contains
the data of 65 patients and 209 samples.
To apply RANSAC, we first preset the basis using some
typical functions: {x−2,x−1,x,x2,x3, log(x),cos(x),(1 −
exp(−x)),exp(x)}. This requires at least K = 9 data
points to estimate the parameters. However, not all the
listed basis functions are useful to get the final model
of drug concentration. Table I shows the experimental
results on each basis function with respect to different
thresholds (tolerable difference between the measured
concentration and the predicted one). In practice, we set
the threshold to be as small as possible to minimize the
difference between the measured concentration values and
the predicted ones. Hence, we combine the first two rows
of the chosen basis functions (scored ‘1’) in Table I:
f (x) = {x−2,x,x3, log(x),cos(x),(1 − exp(−x)),exp(x)}.
Figure 1 shows the AUC (Area Under the drug
Concentration) curve estimated using RANSAC, the
round points denote inliers and the crosses repr sent
outliers.
After determining the basis functions, the drug concen-
trations over the validated dataset is pred ted via SVM
algorithm. W evaluate the drug concentration rediction
Algorithm 1 RANSAC algorit m, where data is a set of
observations, model is a model that can be fitted to data,
K is the minimum number of data points required to fit the
model parameters, N is the number of trials performed by
the algorithm, T is a threshold determining if a data point
fits a model, and bestmodel is the model fitting the highest
number of data points.
Input: data,model,K,N,T
Output: bestmodel
bestinliers← /0
for i= 1→ N do
possibleinliers← SampleUniformly(data,K)
possiblemodel← Fit(model, possibleinliers)
inliers← /0
for all point ∈ data do
if Distance(point,model)< T then
inliers← inliers∪{point}
end if
end for
if |inliers|> |bestinliers| then
bestinliers← inliers
end if
end for
return bestmodel← Fit(model,bestinliers)
a set of outliers for another. Therefore, a predictor built out of
the same set of inliers for a number of new patients might
not be applicable for some others. Hence, it is important
to find an individual set of inliers for each patient. So we
propose to use RANSAC-based personalization method to
solve this task. Previously [2], a ‘closest point’ strategy has
been used which, despite using a much fewer number of
training points (up to 30% of the total number), retains the
initial performance of the original SVM (<3% degradation).
However, that strategy needs a set of predefined weights for
each feature in order to select the ‘closest point’.
Assume that we already have M samples from previous
patients (our training dataset), for each new patient we want
to find a best subset of samples of M to train the SVM.
To do so we treat them as if they were noisy sa ples of a
new patient, and us a RANSAC to remove the outliers. The
whole procedure is detailed in Algorithm 2. The new sampl
from each patient is fir t replicated M tim s to make sure that
it will always be consid red as an inlier. Then RANSAC is
applied to those replicated samples plus to the original M
training samples in order to predict the feature Y as a linear
combination of basis functions of the remaining features X .
The new patient sample is then removed from the inliers and
finally an SVM is trained on the remaining original training
samples to predict the drug concentration of this new patient.
Two clinical scenarios can be applied here: the target
feature Y is set as (1) any feature other than the concentration
value; (2)the measured drug concentration. For the scenario
(1), no invasive blood test is required, while in (2) the drug
concentration value should be measured after the first-dosing.
Algorithm 2 RANSAC-based person lized algorithm, where
training is a set of M training samples, newpatients is an
ordered set containing one sample per new patient , Y is the
index of a particular feature, model,K,N,T are parameters
of the RANSAC algorithm, and bestmodels is an ordered set
containg the SVM model fitting the best each new patient.
Input: training,newpatients,F,model,K,N,T
Output: bestmodels
bestmodels← /0
for all patient ∈ newpatients do
data← {patient, . . . , patient} {|data|=M}
data← data∪ training
inliers← RANSAC(data,model,K,N,T ) {predict Y}
inliers← inliers\{patient}
model← SVM(inliers)
bestmodels← bestmodels∪model
end for
return bestmodels
TABLE I
RANSAC BA IS FUNCTION ANALYSIS WITH SPECT TO DIFFERENT
THRESHOLDS. T: THRESHOLD WITH UNIT [MG/L]. SCORE 0 STANDS FOR
‘UNUSED’ AND SCORE 1 FOR ‘IN USE’.
T x−2 x−1 x x2 x3 log(x) cos(x) 1− exp(−x) exp(x)
250 1 0 1 0 1 1 1 1 0
500 0 0 1 0 0 1 1 0 1
1000 0 1 0 0 0 0 1 1 0
1500 0 1 0 0 0 0 0 0 0
III. EXPERIMENTS AND COMPARISONS
The experiments are conducted on a set of data collected
during patients’ treatment with imatinib, a drug designed to
treat chronic myeloid leukemia and gastrointestinal stromal
tumors [6]. The training dataset consists of 54 patients and
252 samples, while the validation (testing) dataset contains
the data of 65 patients and 209 samples.
To apply RANSAC, we first preset the basis using some
typical functions: {x−2,x−1,x,x2,x3, log(x),cos(x),(1 −
exp(−x)),exp(x)}. This requires at least K = 9 data
points to estimate the parameters. However, not all the
listed basis functions are useful to get the final model
of drug concentration. Table I shows the experimental
results o each basis function with resp ct to different
thresholds (tolerable difference betwee the m asured
concen ration and the predicted one). In practice, we set
the threshold to b as small as possible to minimize the
difference between the mea ured concentration values and
the predicted ones. Hence, we combine the first two rows
of the chosen basis functions (scored ‘1’) in Table I:
f (x) = {x−2,x,x3, log(x),cos(x),(1 − exp(−x)),exp(x)}.
Figure 1 shows the AUC (Area Under the drug
Concentration) curve estimated using RANSAC, the
round points denote inliers and the crosses represent
outliers.
After determining the basis functions, the drug concen-
trations over the validated dataset is predicted via SVM
algorithm. We evaluate the drug concentration prediction
N =
log(1− p)
log(1− (1− u)K)
patient we want to find a best subset of samples of M to 
train the SVM. To do so we treat them as if they were 
noisy samples of a new patient, and use a RANSAC to 
remove the outliers. The whole procedure is detailed in 
Algorithm 2. The new sample from each patient is first 
replicated M times to make sure that it will always be 
considered as an inlier. Then RANSAC is applied to 
those replicated samples plus to the original M training 
samples in order to predict the feature Y as a linear 
combination of basis functions of the remaining features 
X. The new patient sample is then removed from the 
inliers and finally an SVM is trained on the remaining 
original training samples to predict the drug 
concentration of this new patient. 
Two clinical scenarios can be applied here: the 
target feature Y is set as:  
1. Any feature other than the concentration value.  
2. The measured drug concentration.  
For scenario 1, no invasive blood test is required, while 
in 2 the drug concentration value should be measured 
after the first dosing. 
 
4. EXPERIMENTS AND COMPARISONS 
 
The experiments are conducted on a set of data 
collected during patients' treatment with imatinib, a 
drug designed to treat chronic myeloid leukemia and 
gastrointestinal stromal tumors [Widmer2006]. The 
training dataset consists of 54 patients and 252 samples, 
while the validation (testing) dataset contains the data of 
65 patients and 209 samples. 
To apply RANSAC, we first preset the basis using 
some typical functions: {x-2, x-1, x, x2, x3, log(x), cos(x), 
(1-e-x), ex}. This requires at least K=9 data points to 
estimate the parameters. However, not all the listed 
basis functions are useful to get the final model of drug 
concentration. Table 1 shows the experimental results 
on each basis function with respect to different 
thresholds (tolerable difference between the measured 
concentration and the predicted one). In practice, we set 
the threshold to be as small as possible to minimize the 
difference between the measured concentration values 
and the predicted ones. Hence, we combine the first two 
rows of the chosen basis functions (scored '1') in Table 
1: f(x) = {x-2, x, x3, log(x), cos(x), (1-e-x), ex}. Figure 1 
shows the AUC (Area Under the drug Concentration) 
curve estimated using RANSAC, the green points 
denote inliers and the blue represent outliers. 
 After determining the basis functions, the drug 
concentrations over the validated dataset are predicted 
via SVM algorithm. We evaluate the drug concentration 
prediction results of three algorithms (the traditional 
Pharmacokinetic (PK) [Widmer2006], SVM-based 
[You2011], and the proposed RANSAC-SVM) by 
computing an Absolute Difference between the 
Predicted concentration values and the Measured ones 
(ADPM). In practice, we expect ADPM values to be 
small. In our experiments, the RANSAC-SVM 
algorithm enhances the prediction performance by about 
44.7% over the PK method and 42.6% over SVM-based  
Table 1: RANSAC Basis Function Analysis With 
Respect To Different Thresholds. (T: Threshold with 
unit [mg/L]. '0' stands for 'unused' and '1' for 'in use'.) 
 
 
 
Figure 1: AUC (Area Under the plasma concentration 
time Curve) Using RANSAC Analysis. Green points 
are inliers and blue points are outliers. 
 
method, respectively. Around 71% of mean ADPM 
values of RANSAC-SVM results are smaller than 
500mg/L, while this number decreased to around 50% 
for the PK and SVM-based methods. 
For further prediction improvement, we apply two 
personalization scenarios with RANSAC algorithm (see 
Section 2). By choosing different features as X and Y to 
select the individual set of inliers for each new patient, 
we obtain the results shown in Table 2. In imatinib case 
study, the following features are available: {Measured 
Drug Concentration (MDC), Measuring Time (MT), 
Drug Dosage (DD), Age (A), Gender (G), and Body 
Weight (BW)}. Scenario 1 uses any feature other than 
MDC values while scenario 2 uses only MDC to be Y. 
We also compute the enhancement percentages with 
SVM [You2011] (shown as 'v.s. SVM' in the table) and 
Bayesian algorithm [Widmer2006] (shown as 'v.s. 
BAYE' in the table) with the Mean and STD results. 
The number of prediction samples whose predicted 
results are greater than 500mg/L from the measured 
values is denoted as '>500' in the table. 
 The Table 2 shows that the RANSAC-based 
personalization performs slightly better than RANSAC-
SVM algorithm in many cases (1, 2, 3, 4, 5, 6), which 
results from a reduced number of predictions whose 
ADPM values are larger than 500mg/L. Both 
algorithms improve the prediction accuracy compared 
with SVM by around 40%. In scenario 2, BAYE 
outperforms the other two in the average prediction 
values in cases 7, 8, 9. However, in most cases, BAYE 
gives a larger STD value in that the predictions by 
BAYE deviate more from the measured values, while  
Algorithm 1 RANSAC algorithm, where data is a set of
observations, model is a model that can be fitted to data,
K is the minimum number of data points required to fit the
model parameters, N is the number of trials performed by
the algorithm, T is a threshold determining if a data point
fits a model, and bestmodel is the model fitting the highest
number of data points.
Input: data,model,K,N,T
Output: bestmodel
bestinliers← /0
for i= 1→ N do
possibleinliers← SampleUniformly(data,K)
possiblemodel← Fit(model, possibleinliers)
inliers← /0
for all point ∈ data do
if Distance(point,model)< T then
inliers← inliers∪{point}
end if
end for
if |inliers|> |bestinliers| then
bestinliers← inliers
end if
end for
return bestmodel← Fit(model,bestinliers)
a set of outliers for another. Therefore, a predictor built out of
the same set of inliers for a number of new patients might
not be applicable for some others. Hence, it is important
to find an individual set of inliers for each patient. So we
propose to use RANSAC-based personalization method to
solve his task. Previously [2], a ‘closes point’ strate y has
been used which, des ite using a much fewer number of
training points (up to 30% of the total number), retains the
initial performance of the original SVM (<3% degradation).
However, that strategy needs a set of predefined weights for
each feature in order to select the ‘closest point’.
Assume that we already have M samples from previous
patients (our training dataset), for each new patient we want
to find a best subset of samples of M to train the SVM.
To do so we treat them as if they were noisy samples of a
new patient, and use a RANSAC to remove the outliers. The
whol procedure is detailed in Algorithm 2. The new sample
from each patient s first replicat d M t mes to make sure that
it will always be considered as an inlier. Th n RANSAC is
applied to those replicated samples plus to the original M
training samples in order to predict the feature Y as a linear
combination of basis functions of the remaining features X .
The new patient sample is then removed from the inliers and
finally an SVM is trained on the remaining original training
samples to predict the drug concentration of this new patient.
Two clinical scenarios can be applied here: the target
feature Y is set as (1) any feature other than the concentration
value; (2)the measured drug concentration. For the scenario
(1), no invasive blood test s required, while in (2) the drug
concentration value should b m asur d aft r th first- osing.
Algorithm 2 RANSAC-based personalized algorithm, where
training is a set of M training samples, newpatients is an
ordered set containing one sample per new patient , Y is the
index of a particular feature, model,K,N,T are parameters
of the RANSAC algorithm, and bestmodels is an ordered set
containg the SVM model fitting the best each new patient.
Input: training,newpatients,F,model,K,N,T
Output: bestmodels
bestmodels← /0
for all patient ∈ newpatients do
data← {patient, . . . , patient} {|data|=M}
data← data∪ training
inliers← RANSAC(data,model,K,N,T ) {predict Y}
inliers← inliers\{patient}
model← SVM(inliers)
bestmodels← bestmodels∪model
end for
return bestmodels
TABLE I
RANSAC BASIS FUNCTION ANALYSIS WITH RESPECT TO DIFFERENT
THRESHOLDS. T: THRESHOLD WITH UNIT [MG/L]. SCORE 0 STANDS FOR
‘UNUSED’ AND SCORE 1 FOR ‘IN USE’.
T x−2 x−1 x x2 x3 log(x) cos(x) 1− exp(−x) exp(x)
250 1 0 1 0 1 1 1 1 0
500 0 0 1 0 0 1 1 0 1
1000 0 1 0 0 0 0 1 1 0
1500 0 1 0 0 0 0 0 0 0
III. EXPERIMENTS AND COMPARISONS
The experiments are conducted on a set of data collected
during patients’ treatment with imatinib, a drug designed to
treat chronic myeloid leukemia and gastrointestinal stromal
tumors [6]. The training dataset consists of 54 patients and
252 samples, while the validation (testing) dataset contains
the data of 65 patients and 209 samples.
To apply RANSAC, we first preset the basis using some
typical functions: {x−2,x−1,x,x2,x3, log(x),cos(x),(1 −
exp(−x)),exp(x)}. This requires at least K = 9 data
points to estimate the parameters. However, not all the
listed basis functions are useful to get the final model
of drug concentration. Table I shows the experimental
results on each basis function with respect to different
thresholds (tolerable difference between the measured
concentration and the predicted one). In practice, we set
the threshold to be s small as possible to minimize the
difference between the measured concentration values and
the pre icted ones. Hence, we combine the first two rows
of the chosen basis functions (scored ‘1’) in Table I:
f (x) = {x−2,x,x3, log(x),cos(x),(1 − exp(−x)),exp(x)}.
Figure 1 shows the AUC (Area Under the drug
Concentration) curve estimated using RANSAC, the
round points denote inliers and the crosses represent
outliers.
After determining the basis functions, the drug concen-
trations over the validated dataset is predicted via SVM
algorithm. We evaluate the drug concentration prediction
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Table 2: Comparisons Of The Drug Concentration 
Predictions Using RANSAC-based Personalization 
(RPER), RANSAC-SVM (RSVM), SVM [You2011], 
And Bayesian Estimation (BAYE) [Widmer2006]. 
('>500': Number of prediction samples that are more 
than 500mg/L different from the measured values.) 
 
 
the other two algorithms estimate the concentration 
values without a large deviation. Hence, we can see that 
the proposed algorithms are robust to predict the 
concentrations more accurately for any individual 
patient, while Bayesian algorithm only predicts well for 
some patients and less accurate for the others. 
 
 
5. CONCLUSIONS 
This paper presents a RANSAC-based SVM algorithm 
to estimate drugs concentrations. RANSAC filters out 
the outliers in the input datasets to reduce the number of 
measurement errors. It exceeds the traditional 
Pharmacokinetic and SVM-based prediction methods 
by more than 40% in accuracy. The paper also 
introduces a way to personalize drug concentration 
prediction with the RANSAC algorithm. Experiments 
show that it enhances the proposed initial RANSAC-
based SVM algorithm in many cases. 
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Fig. 1. AUC (Area Under the plasma concentration time Curve) using
RANSAC analysis. Green points are inliers and blue points are outliers.
results of three algorithms (the traditional Pharmacokinetic
(PK) [6], SVM-based [2], and the proposed RANSAC-SVM)
by computing an Absolute Difference between the Predicted
concentration values and the Measured ones (ADPM). In
practice, we expect ADPM values to be small. In our
experiments, the RANSAC-SVM algorithm enhances the
prediction performance by about 44.7% over the PK method
and 42.6% over SVM-based method, respectively. Around
71% of mean ADPM values of RANSAC-SVM results
are smaller than 500mg/L, while this number decreased to
around 50% for the PK and SVM-based methods.
For further prediction improvement, we apply two per-
sonalization scenarios with RANSAC algorithm (see Section
II). By choosing different features as X and Y to select the
individual set of inliers for each new patient, we obtain the
results shown in Table II. In imatinib case study, the follow-
ing features are available: {Measured Drug Concentration
(MDC), Measuring Time (MT), Drug Dosage (DD), Age
(A), Gender (G), Body Weight (BW)}. Scenario (1) uses any
feature other than MDC values while scenario (2) uses only
MDC to be Y . We also compute the enhancement percentages
with SVM [2] (v.s. SVM) and Bayesian algorithm [6] (v.s.
BAYE) in the Mean and STD results.
The table shows that the RANSAC-based personalization
performs slightly better than RANSAC-SVM algorithm in
many cases (1, 2, 3, 4, 5, 6), which results from a reduced
number of predictions whose ADPM values are larger than
500mg/L. Both algorithms improve the prediction accuracy
compared with SVM by around 40%. In scenario 2, BAYE
outperforms the other two in the average prediction values
in cases 7, 8, 9. However, in most cases, BAYE gives a
larger STD value in that it predicts the results with much
less accuracy for some patient points. while the other two
algorithms estimate the concentration values without a large
deviation. Hence, we can see that the proposed algorithms are
robust to predict the concentrations more accurately for any
individual patient, while Bayesian algorithm only predicts
well for some patients and less accurate for the others.
IV. CONCLUSIONS
This paper presents a RANSAC-based SVM algorithm
to estimate drugs concentrations. RANSAC filters out the
TABLE II
COMPARISONS OF THE DRUG CONCENTRATION PREDICTIONS USING
RANSAC-BASED PERSONALIZATION (RPER), RANSAC-SVM
(RSVM), SVM [2], AND BAYESIAN ESTIMATION (BAYE) [6]. > 500:
NUMBER OF PREDICTION SAMPLES THAT ARE GREATER THAN 500MG/L.
Scenario 1: without blood measurement after first-dosing
case Features Method Mean v.s. SVM STD v.s. SVM > 500
1 Y =BW RPER 258.60 42.10% 239.97 39.62% 6
X =MT RSVM 261.00 41.56% 240.64 39.45% 8
2 Y =A RPER 222.39 50.21% 168.56 57.59% 3
X =MT RSVM 224.89 49.65% 168.40 57.63% 4
3 Y =G RPER 282.21 36.81% 258.92 34.85% 7
X =MT RSVM 283.90 36.44% 260.56 34.44% 9
4 Y =DD RPER 212.72 52.37% 170.93 56.99% 1
X =MT RSVM 213.35 52.46% 170.99 56.97% 1
5 Y =A RPER 235.68 47.23% 181.60 54.31% 6
X =BW RSVM 243.79 45.42% 184.47 53.58% 6
Scenario 2: with blood measurement after first-dosing
case Features Method Mean v.s. BAYE STD v.s. BAYE > 500
6 Y =MDC RPER 229.59 8.02% 211.34 43.65% 2
X =MT RSVM 239.58 4.01% 202.48 46.01% 3
7 Y =MDC RPER 244.67 -17.74% 168.92 20.09% 10
X =DD RSVM 232.77 -12.02% 168.79 20.16% 7
8 Y =MDC RPER 401.31 -103.42% 363.09 -89.80% 21
X =G RSVM 243.98 -23.67% 184.74 3.43% 7
9 Y =MDC RPER 279.63 -15.30% 196.42 46.58% 8
X =A RSVM 247.46 -2.04% 199.13 45.84% 5
10 Y =MDC RPER 219.33 8.18% 173.5 53.53% 3
X =BW RSVM 212.23 11.15% 155.22 58.43% 2
outliers in the input datasets to reduce the number of mea-
surement errors. It exceeds the traditional Pharmacokinetic
and SVM-based prediction methods by more than 40% in
accuracy. The paper also introduces a way to personalize
drug concentration prediction with the RANSAC algorithm.
Experiments show that it enhances the proposed initial
RANSAC-based SVM algorithm in many cases.
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